Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by equities researchers at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating in a note issued to investors on Friday, Briefing.com reports. The brokerage currently has a $55.00 target price on the biotechnology company's stock.
https://www.marketbeat.com/instant-alerts/nasdaq-enta-a-buy-or-sell-right-now-2021-01/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.